Corporate Milestones

Following is an overview of Biosite’s most noteworthy accomplishments to date, including product launches, the initiation of important research collaborations and partnerships, and significant marketing achievements.

June 2007
Inverness Announces Successful Completion of Tender Offer for Biosite

October 2005
Biosite moves into its new 26 acre corporate campus facility in Sorrento Mesa. The project, once complete, will accommodate up to a total of 800,000 square feet.

August 2005
Biosite receives CLIA Waiver for the Triage BNP Test.

July 2005
Biosite announces commercialization of its Triage Stroke Panel in the European Union. The CE Marked Triage Stroke Panel is a rapid immunoassay intended to aid in the assessment and diagnosis of stroke. The test is currently not approved for sale in the United States.

March 2005
Biosite receives FDA clearance to market the Triage TOX Drug Screens with Acetaminophen, the first drug screen to include a rapid, point-of-care test for the qualitative detection of acetaminophen in urine.

January 2005
Biosite announces U.S. filing of its premarket approval application for Triage Stroke Panel.

December 2004
Biosite announces FDA clearance for Triage D-Dimer Test, an aid in the assessment and evaluation of patients suspected of having thromboembolic events, including pulmonary embolism (PE) and deep vein thrombosis (DVT), which are common and potentially lethal conditions.

September 2004
Biosite receives CE mark for Triage Profiler Shortness of Breath Panel, a diagnostic symptom panel that is intended to accelerate and improve emergency department evaluation of shortness of breath, which ranks among the top reasons for emergency department visits.

July 2004
Biosite and Henry Schein sign distribution agreement for physician office segment.

June 2004
Biosite receives FDA clearance for Triage Profiler Shortness of Breath Panel, a diagnostic symptom panel that is intended to accelerate and improve emergency department evaluation of shortness of breath, which ranks among the top reasons for emergency department visits.

February 2004
Biosite announces license agreement with the Cleveland Clinic for MPO.

January 2004
Biosite receives FDA clearance to market the Triage BNP Test for use with capillary whole blood, as obtained by a finger prick.

January 19, 2004
Biosite expands reach into Europe with two new offices in the United Kingdom and Belgium.

November 3, 2003
Biosite announces the launch of a new subsidiary, Biosite GmbH, which will manage direct sales and distribution of Biosite’s products in Germany.

July 7, 2003
Biosite announces the launch of a new subsidiary, Biosite France SAS, which will manage direct sales and distribution of Biosite's products in France.

May 15, 2003
Biosite initiates sales to physician office practices.

March 6, 2003
Biosite receives FDA clearance to market the Triage Cardio ProfilER as an aid in the diagnosis of heart attack, an aid in the diagnosis and assessment of severity of congestive heart failure (also referred to as heart failure), and for the risk stratification of patients with acute coronary syndromes.

March 19, 2002
Results from the “Breathing Not Properly” BNP Multinational Study are released at the American College of Cardiology Scientific Session 2002. Findings from the Biosite sponsored study demonstrate the utility of BNP as an aid in the diagnosis of congestive heart failure in the study. BNP demonstrates a sensitivity of 90 percent, specificity of 74 percent and an accuracy of 81.1 percent in differentiating heart failure from other causes of dyspnea.

January 17, 2002
Biosite receives FDA clearance to market the Triage TOX Drug Screen, a second-generation drug test.

July 31, 2001
Biosite announces that its stroke marker discovery program has yielded an initial panel of markers capable of detecting stroke with high levels of sensitivity and specificity. Product development is initiated.

March 2001
Biosite reports advances in developing a protein microarray platform.

November 2000
Biosite receives FDA clearance to market the Triage BNP Test, an aid in the rapid diagnosis of congestive heart failure.

October 2000
Biosite collaborates with the Thrombolysis In Myocardial Infarction (TIMI) Study Group in launching a program to identify proteins to diagnose acute coronary syndromes, or ischemic heart disease.

June 2000
Biosite and Medarex Inc. announce the launch of an alliance aimed at accelerating drug research via Trans-Phage TechnologySM.

November 1999
Biosite introduces the Triage Cardiac System in Europe.

September 1999
Through Biosite Discovery, Biosite initiates a research program to develop a stroke diagnostic. The company will collaborate with Duke University to facilitate marker discovery efforts.

March 1999
Biosite launches Biosite Discovery, an internal research program aimed at building a portfolio of novel diagnostic protein markers.

February 1999
Biosite launches, in the United States, the Triage Cardiac System, a rapid blood test to aid in the diagnosis of heart attack.

October 1998
Biosite receives FDA clearance to market the Triage Parasite Panel, a test used to aid in the diagnosis of intestinal parasitic disease.

March 1998
Biosite receives FDA clearance to market the Triage C. difficile Panel, an aid in the rapid diagnosis of C.difficile associated disease.

February 1997
Biosite completes an initial public offering. BSTE is officially traded on the Nasdaq National Market with an offering price of $12.00 per share.

February 1992
Biosite commercializes its first product, the Triage® Drugs of Abuse Panel.

March 1988
Biosite is officially incorporated in Delaware as Biosite Diagnostics Incorporated.